Results 201 to 210 of about 112,575 (266)

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Pharmacogenomics knowledge and implementation readiness among community pharmacists in Jordan: A national cross-sectional study. [PDF]

PLoS One
Al-Kubaisi KA, Abdel-Qader DH, Al Mazrouei N, Ibrahim R, Alhusban A.   +4 more
europepmc   +1 more source

Pharmacist prescribers.

Journal of primary health care, 2010
Wheeler, Amanda, Hale, Andrew, Jensen, Maree, Coombes, Ian, Stokes, Julie, Stowasser, Danielle, Nissen, Lisa   +6 more
openaire   +2 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Verification of the value of optimization of the medication-related clinical decision support system in China, a hospital-based study. [PDF]

JAMIA Open
Ran S, Gu D, Xie J, Jiang K, Yao N, Fang Z, Asakawa T, Zhang N, Fang H.   +8 more
europepmc   +1 more source

Differences in Opioid Prescribing by Urban and Rural Pharmacists in Nova Scotia, Canada-A Time Series Analysis from 2018 to 2022. [PDF]

Pharmacy (Basel)
Chisholm E, Zhang Y, Sanyal C.
europepmc   +1 more source

Pharmacists Unite!

The Canadian Journal of Hospital Pharmacy, 2011
openaire   +3 more sources

Reconstructing the professional role of pharmacists in China from the perspective of public value theory: challenges and institutional pathways. [PDF]

J Pharm Policy Pract
Han K, Wu S, Lin F, Nie X, Shi L, Guan X.   +5 more
europepmc   +1 more source